Maya Gottfried
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 56
- Lung Cancer Diagnosis and Treatment 15
- Renal cell carcinoma treatment 13
- Prostate Cancer Treatment and Research 10
- Oncology 78
- Cancer Immunotherapy and Biomarkers 30
- Lung Cancer Research Studies 23
- Colorectal Cancer Treatments and Studies 17
- Co-authors
- Delvys Rodríguez‐Abreu (18 shared papers)Tibor Csőszi (17 shared papers)Nir Peled (17 shared papers)Ali Tafreshi (12 shared papers)Suman Rao (12 shared papers)Rina Hui (12 shared papers)Sinéad Cuffe (12 shared papers)Katsuyuki Hotta (12 shared papers)
- Journals
- Journal of Clinical Oncology (48 papers)Annals of Oncology (22 papers)Journal of Thoracic Oncology (13 papers)Lung Cancer (6 papers)European Journal of Cancer (5 papers)
- Partner nations
- IsraelUnited StatesGermany
In The Last Decade
Maya Gottfried
151 papers receiving 13.4k citations
Maya Gottfried's Hit Papers
Peers
Comparison fields: 5 of 123
- Oncology 8.6k
- Pulmonary and Respiratory Medicine 5.1k
- Cancer Research 1.2k
- Immunology 1.6k
- Pathology and Forensic Medicine 506
Countries citing papers authored by Maya Gottfried
This map shows the geographic impact of Maya Gottfried's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maya Gottfried with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maya Gottfried more than expected).
Fields of papers citing papers by Maya Gottfried
This network shows the impact of papers produced by Maya Gottfried. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maya Gottfried. The network helps show where Maya Gottfried may publish in the future.
Co-authors
The 25 scholars most cited alongside Maya Gottfried, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 157 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 7183 |
| 2 | Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Hit paper breakdown → | 2019 | 1144 |
| 3 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Hit paper breakdown → | 2014 | 697 |
| 4 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Hit paper breakdown → | 2021 | 654 |
| 5 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study Hit paper breakdown → | 2020 | 508 |
| 6 | Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study Hit paper breakdown → | 2022 | 260 |
| 7 | 2017 | 257 | |
| 8 | 2011 | 228 | |
| 9 | 1996 | 204 | |
| 10 | 2012 | 197 | |
| 11 | 2000 | 177 | |
| 12 | 2018 | 133 | |
| 13 | 2008 | 79 | |
| 14 | 2009 | 76 | |
| 15 | 2012 | 75 | |
| 16 | 2020 | 73 | |
| 17 | 2010 | 64 | |
| 18 | 2020 | 62 | |
| 19 | 2001 | 60 | |
| 20 | 1999 | 60 |
About Maya Gottfried
Maya Gottfried is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 157 papers that have together received 13.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (56 papers), Cancer Immunotherapy and Biomarkers (30 papers), Lung Cancer Research Studies (23 papers), Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Diagnosis and Treatment (15 papers), Renal cell carcinoma treatment (13 papers), Cancer Genomics and Diagnostics (12 papers) and Prostate Cancer Treatment and Research (10 papers). The work is most often cited by research in Oncology (8.6k citations), Pulmonary and Respiratory Medicine (5.1k citations), Cancer Research (1.2k citations), Immunology (1.6k citations) and Pathology and Forensic Medicine (506 citations). Maya Gottfried has collaborated with scholars based in Israel, United States and Germany. Frequent co-authors include Delvys Rodríguez‐Abreu, Tibor Csőszi, Nir Peled, Ali Tafreshi, Suman Rao, Rina Hui, Sinéad Cuffe, Katsuyuki Hotta, Julie R. Brahmer and Andrew Robinson. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.